Drug intelligence / Profile preview

heat-killed lactobacillus paracasei

Development stage
Unknown
Lead developer
Kyowa Kirin
Modality
Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration
Oral
01

Overview

Heat-killed lactobacillus paracasei refers to preparations of the probiotic bacterium Lacticaseibacillus paracasei that have been inactivated by heat and are therefore non-viable. Unlike live probiotics, these are considered “postbiotics” and may retain immunomodulatory and anti-inflammatory activities despite loss of viability. Specific heat-killed strains have been studied and shown to reduce nasal symptoms in allergic rhinitis, lower inflammatory cytokines (such as IL-6), and provide protective or modulatory effects in conditions like influenza, osteoporosis, and inflammatory bowel disease. The inactivation process typically involves heating bacteria at 90°C for 30 minutes, rendering them non-replicating but potentially bioactive through structural bacterial components[5][3][7][2]. Mechanistically, these effects are mediated through interactions with the immune system, reduction of inflammatory mediators, modulation of gut barrier function, and potentially other host–microbiome interactions[5][7]. Applications are under investigation in allergic rhinitis, osteoporosis, gut barrier dysfunction, and potentially mood or stress. Commercial development is limited to dietary supplements and functional foods; no heat-killed formulations are approved as pharmaceuticals[3][7][5].

Brand names
PoZibioLAC-Shieldelénzia FIX
Other names
heat-killed lacticaseibacillus paracaseiheat-inactivated lactobacillus paracaseiheat-killed L. paracaseiheat-inactivated L. paracasei
02

Targets

TLR2/TLR6 (Toll-like receptor 2/Toll-like receptor 6 pattern recognition receptor complex)

Beyond the preview

Go deeper on heat-killed lactobacillus paracasei.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on heat-killed lactobacillus paracasei.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call